ADMA Biologics, Inc. (ADMA) Earnings History
Profitable19 years of earnings data (2007–2025) · Positive TTM net income
Loading earnings history...
ADMA Biologics, Inc. (ADMA) Earnings Overview
As of June 22, 2026, ADMA Biologics, Inc. (ADMA) reported trailing twelve-month net income of $165M, reflecting -25.9% year-over-year growth. The company earned $0.69 per diluted share over the past four quarters, with a net profit margin of 28.8%.
Looking at the long-term picture, ADMA's historical earnings data spans multiple years. The company achieved its highest annual net income of $198M in fiscal 2024.
ADMA Biologics, Inc. maintains industry-leading profitability with a gross margin of 57.4%, operating margin of 37.5%, and net margin of 28.8%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →
Compared to peers including GRFS ($416M net income, 5.3% margin), BIO ($169M net income, 29.4% margin), PRPH (-$15M net income, -339.3% margin), ADMA has outperformed on profitability metrics. Compare ADMA vs GRFS →
ADMA Earnings vs Peers
Earnings metrics vs comparable public companies
ADMA Historical Earnings Data (2007–2025)
19 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $147M | -25.7% | $191M | $0.60 | 28.8% | 37.5% |
| 2024 | $198M | +800.0% | $139M | $0.81 | 46.4% | 32.6% |
| 2023 | -$28M | +57.2% | $22M | $-0.13 | -10.9% | 8.4% |
| 2022 | -$66M | +8.0% | -$39M | $-0.43 | -42.8% | -25.5% |
| 2021 | -$72M | +5.4% | -$58M | $-0.61 | -88.5% | -72.1% |
| 2020 | -$76M | -56.9% | -$65M | $-1.02 | -179.4% | -153.8% |
| 2019 | -$48M | +26.6% | -$41M | $-1.05 | -164.5% | -141.1% |
| 2018 | -$66M | -50.2% | -$60M | $-1.45 | -387.1% | -354.9% |
| 2017 | -$44M | -124.2% | -$39M | $-1.91 | -192.3% | -172.7% |
| 2016 | -$20M | -8.6% | -$17M | $-1.61 | -183.1% | -162.6% |
| 2015 | -$18M | -6.9% | -$16M | $-1.73 | -250.4% | -216.1% |
| 2014 | -$17M | -8.3% | -$16M | $-1.81 | -284.2% | -270.8% |
| 2013 | -$16M | -112.7% | -$15M | $-2.38 | -506.2% | -490.4% |
| 2012 | -$7M | -27493.8% | -$8M | $-1.39 | -653.0% | -707.4% |
| 2011 | $-26,460 | -28.9% | $-26,464 | $-0.00 | - | - |
| 2010 | $-20,526 | +99.9% | $-20,530 | $-0.00 | - | - |
| 2009 | -$20M | +19.6% | -$20M | $-0.02 | - | - |
| 2008 | -$25M | +16.2% | -$25M | $-0.02 | - | - |
| 2007 | -$30M | - | -$30M | $-0.01 | - | - |
Download Data
Export ADMA earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
19+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ADMA — Frequently Asked Questions
Quick answers to the most common questions about buying ADMA stock.
What is ADMA earnings per share (EPS)?
ADMA trailing twelve-month (TTM) diluted EPS is $0.69, reflecting -25.9% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2007 to 2025 is available in the table on this page.
What is ADMA Biologics, Inc.'s net income?
ADMA Biologics, Inc. (ADMA) trailing twelve-month net income is $165M as of 2025. Earnings declined -25.9% year-over-year. ADMA Biologics, Inc. has been profitable for 2 consecutive years.
Is ADMA profitable?
Yes, ADMA is profitable with a TTM net income of $165M and a net profit margin of +28.8%. ADMA Biologics, Inc. has generated profits for 2 consecutive years.
What is ADMA's earnings growth rate?
ADMA compound annual EPS growth rates (CAGR): 1-Year: -25.9%, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2007 to 2025.
What are ADMA's profit margins?
ADMA Biologics, Inc. net profit margin is +28.8%, operating margin is +37.5%, and gross margin is +57.4%. Above-average net margins reflect strong pricing power and competitive moat. Return on Equity is +35.6%.
Is ADMA growing earnings?
ADMA earnings are declining — EPS fell -25.9% year-over-year. TTM net income dropped to $165M. This contrasts with the 5-year CAGR of N/A.
What was ADMA's best earnings year?
ADMA Biologics, Inc.'s highest annual net income on record is $198M, achieved in fiscal year 2024. Earnings history on this page spans 2007 to 2025 and includes all annual and quarterly figures.
What were ADMA's earnings last quarter?
ADMA's most recent reported quarter was Q1 2026. Net income was $45M with diluted EPS of $0.19. For a full breakdown of all quarters, see the quarterly earnings table on this page.